Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$20.47M+166.72%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Roger E. Susi
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 166
- Beta
- 0.90
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 51.07
Financials
Revenue
$20.47M+166.7%Net Income
$5.22M+234.4%EBITDA
$6.80M+162.2%Free Cash Flow
$5.75M+75.6%EPS (diluted)
$0.41+215.4%Shares Outstanding (diluted)
12.87M+8.5%Operating Expenses
$8.77MCash & Debt
$59.08MReturn of Capital
$2.56MRevenue by Segment (annual)
$26.43MDividend per Share
$0.20Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $83.81M | $22.48M | $1.77 |
| 2024 | $73.24M | $19.23M | $1.52 |
| 2023 | $65.56M | $17.19M | $1.36 |
| 2022 | $53.30M | $12.83M | $1.02 |
| 2021 | $41.81M | $9.33M | $0.76 |
| 2020 | $31.72M | $1.37M | $0.11 |
| 2019 | $38.52M | $9.63M | $0.85 |
| 2018 | $30.44M | $6.30M | $0.52 |
| 2017 | $23.08M | $499.8K | $0.05 |
| 2016 | $32.50M | $7.21M | $0.67 |
| 2015 | $31.59M | $7.53M | $0.68 |
| 2014 | $15.65M | $2.05M | $0.23 |
| 2013 | $11.34M | $1.94M | $0.19 |
| 2012 | $7.69M | $966.1K | $0.09 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from IRMD's reported EPS growth of 25.5% a year over 13 years.
- EPS in 5 years
- $5.50
- Implied price
- $302.57
- Return from $86.73
- 28.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $150.43 — today's price is already 42.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 39 | 47 | 55 | 63 | 71 |
|---|---|---|---|---|---|
| 15.5% | 10.3% | 14.5% | 18.2% | 21.4% | 24.4% |
| 20.5% | 15.1% | 19.5% | 23.3% | 26.7% | 29.7% |
| 25.5% | 19.9% | 24.4% | 28.4% | 31.9% | 35.1% |
| 30.5% | 24.6% | 29.4% | 33.5% | 37.2% | 40.5% |
| 35.5% | 29.4% | 34.3% | 38.6% | 42.4% | 45.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+42.86%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Neutral
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 5th Annual ROTH Healthcare Opportunities Conference.
View source ↗ - Newsgurufocus.com·18d ago·Negative
iRadimed Corp (IRMD) Stock Down 3.8% but Still Overvalued -- GF Score: 92/100 On September 04, 2026, iRadimed Corp (IRMD) shares fell 3.8%, currently trading at $83.45. The stock has seen a notable decline, with a 52-week high of $107.90
View source ↗
Earnings
Mon, Nov 2(in 6 weeks)
Consensus estimate $0.52 per share
Typical surprise +4.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$0.46 vs $0.44beat
- Fri, May 1$0.49 vs $0.45beat
- Tue, Feb 10$0.54 vs $0.49beat
- Mon, Nov 3$0.47 vs $0.48miss
- Fri, Aug 1$0.49 vs $0.45beat
- Mon, May 5$0.42 vs $0.43miss
Estimates and results for IRMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IRMD officers and directors.
- Bought
- —
- Sold
- $13.3m
0 trades
87 trades
- Allen Monty Ksold
- Allen Monty Ksold
- Scharen-guivel Hilda Frederiquesold
- Scharen-guivel Hilda Frederiquesold
- Susi Roger E.sold
- Susi Roger E.sold
- Susi Roger E.sold
- Susi Roger E.sold
13 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IRMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.